Salt Lake City cardiac medical device developer and marketer Foldax has appointed medical technology veteran Gregory D. Casciaro as CEO of the company. He has more than 30 years of experience with medical device companies in all phases of development.
As president and CEO of Access Closure, General Surgical Innovations, Orques and XTNT, he led all four companies to successful exits via acquisitions. His experience also includes serving as president and CEO for Cardiac Dimensions and in executive and management roles at Guidant’s Devices for Vascular Intervention division and North American Instrument Corp. Currently, he serves on the board of directors for Colospan, Cytokind, Tulavi Therapeutics and KL Acquisition Corp., and has held board roles with AngioDynamics, Apama Medical, Dextera Surgical, Kerberos Proximal Solutions and QT Vascular.
“Greg has enjoyed tremendous success leading and growing medtech companies, many of them in the cardiovascular space. His strategic guidance and leadership helped many of them navigate sometimes complex paths to market and resulted in successful acquisitions by industry leaders,” said Ken Charhut, executive chairman of the board for Foldax. “We are delighted that Greg is joining us as we execute on our mission to bring a transformational heart valve platform to clinics and patients around the world.”
“Foldax has a groundbreaking technology with the potential to solve perennial problems that have plagued heart valves for decades, and I am excited to lead the team working to make this promise a reality,” said Casciaro. “Reimagining how heart valves are designed and manufactured is a unique and special opportunity that I believe can benefit from my wealth of experiences.”